Phase II trial of a novel platinum analog, SKI 2053R, in patients with previously untreated extensive-stage small-cell lung cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 22, Issue 5, 1999, Pages 495-498

  Zang, Dae Young ^a,b   Lee, Kyoo Hyung ^a,b   Lee, Jung Shin ^a,b   Lee, Je Hwan ^a,b   Kim, Woo Kun ^a,b   Kim, Sang Hee ^a,b   Kim, Won Dong ^a,b   Kim, Dong Soon ^a,b   Kim, Joo Hang ^c   Kim, Byung Soo ^c   Cho, Yong Baik ^d   Kim, Dae Kee ^d   Kim, Key H ^d  

^a University of Ulsan   (South Korea)

^b Asan Medical Center   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d SK Chemicals   (South Korea)

Author keywords

SKI 2053R; Small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; EPTAPLATIN; PLATINUM DERIVATIVE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; DRUG STRUCTURE; FEMALE; HUMAN; LEUKOPENIA; LIVER TOXICITY; LUNG SMALL CELL CANCER; MALE; NAUSEA; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; FEMALE; HEMATOLOGIC DISEASES; HUMANS; KOREA; LUNG NEOPLASMS; MALE; MALONATES; MIDDLE AGED; NAUSEA; ORGANOPLATINUM COMPOUNDS; SURVIVAL RATE;

EID: 0343569839     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199910000-00015     Document Type: Article

References (17)

1. Ihde DC, Pass HI, Glatstein E. Small cell lung cancer. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven, 1997:911-49.
2. Murray NM, Peter C, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 1993;11:336-44.
3. Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987;316:912-8.
4. Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994;12:2022-34.
5. Kim D-K, Kim G, Gam J, et al. Synthesis and antitumor activity of a series of [2-substituted-4,5-bis(aminomethyl)-1,3-dioxolane]-platinum(II) complexes. J Med Chem 1994;37:1471-85.
6. Kim D-K, Kim H-T, Tai JH, et al. Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II) , as determined by ex vivo pharmacodynamics. Cancer Chemother Pharmacol 1995;37:1-6.
7. Kim NK, Bang Y-J, Heo DS, et al. A phase I clinical and pharmacokinetic study of SKI 2053R, a new platinum analog in patients with malignancies [Abstract 1556]. Proc Am Soc Clin Oncol 1995;14:479.
8. Kim NK, Im SA, Jung CW, et al. An active new platinum analog SKI 2053R in patients with advanced gastric adenocarcinoma: phase II clinical trial [Abstract 1044]. Proc Am Soc Clin Oncol 1997;16:294a.
9. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
10. Aisner J. Identification of new drugs in small cell lung cancer: phase II agents first? Cancer Treat Rep 1987;71:1131-3.
11. Ettinger DS. Evaluation of new drugs in untreated patients with small-cell lung cancer: its time has come. J Clin Oncol 1990;8: 374-7.
12. Moore TD, Korn EL. Phase II trial design consideration for small-cell lung cancer. J Natl Cancer Inst 1992;84:150-4.
13. Blackstein M, Eisenhauer EA, Wierzbicki R, Yoshida S. Epirubicin in extensive small-cell lung cancer: a phase II study in previously untreated patients. A National Cancer Institute of Canada Clinical Trial Group study. J Clin Oncol 1990;8:385-9.
14. Cormier Y, Eisenhauser E, Mudal A, et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC): a study of the National Cancer Institute of Canadian Trials Group. Ann Oncol 1994;5:283-5.
15. Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1995;13:1430-5.
16. Smith IE, Harland SJ, Robinson BA, et al. Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer. Cancer Treat Rep 1985;69:43-6.
17. Kim H-T. Kim D-K, Cho Y-B, et al. Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cismalonato[(4R,5R)-4,5-bis(aminomethy)-2-isopropyl-1.3-dioxolane]platinum(II). Cancer Chemother Pharmacol 1998;41:109-16.